The French neurotropic vaccine, or FNV, was used extensively in Africa to control yellow fever (YF). 
Introduction
The genus Flavivirus of the family Flaviviridae is a group of enveloped, single-stranded, positive-sense, RNA viruses containing approximately 70 members (Chambers et al., 1990) . The RNA genome is approximately 11 kb in length and encodes three structural proteins [core (C), membrane (M), envelope (E)] and eight non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, 2K, NS4B and NS5). The gene order has been established as 5' C-preM (M)-E-NS1-NS2A-NS2B-NS3-NS4A-2K-NS4B-NS5 3' (Rice et al., 1985; Lin et al., 1993) . Yellow fever (YF) virus is the prototype member of the genus Flavivirus and causes the disease in humans known as YF. Wild-type YF virus is mainly viscerotropic causing liver damage in humans which leads to yellow skin discoloration and haemorrhagic fever. The disease has been recognized for several hundred years and is transmitted between vertebrate hosts by mosquitoes. Two separate live attenuated vaccine strains, 17D and French neurotropic vaccine (FNV), were developed from wild-type strains Asibi and French viscerotropic virus (FVV), respectively (reviewed in Barrett, 1987) . Attenuation of wild-type Asibi strain was achieved by passage in monkeys, cultures of embryonic mouse tissue, and minced whole chick embryo with and without nervous tissue. The 17D strain has been in use for over 50 years and is one of the safest and most efficacious viral vaccines in use today. It has been administered to more than 260 million people with a seroconversion rate of greater than 95% and a very low rate of postvaccinal accidents (Jennings et al., 1994) . Comparison of the genomes of Asibi and 17D-204 viruses revealed 68 nucleotide differences that lead to 32 amino acid substitutions. This corresponds to 0"6 % overall sequence divergence during 243 passages. (Rice et al., 1985; Hahn et al., 1987) .
The FNV virus was developed by passage of the wildtype strain FVV 128 times through mouse brain (Mathis Wang and others et al., 1928; Barrett, 1987) and was widely used as a vaccine strain, especially in French speaking areas of Africa (Barrett, 1987) . Comparison of immunity induced in humans by the FNV and 17D vaccines revealed that FNV was more immunogenic than 17D (Smith, 1951; Dick, 1956) . Unfortunately, the risk of post-vaccinal encephalitis in children following FNV immunization was too high and its use was eventually discontinued in 1980. However, since the molecular basis of attenuation of YF virus is unclear, the FNV virus offers another attenuated variant of YF virus which can be examined at the molecular level to complement both biological and antigenic studies performed previously (Theiler, 1951; Fitzgeorge & Bradish, 1980; Gould et al., 1985 Gould et al., , 1989 Deubel et al., 1986; Sil et al., 1992) . Due to their different passage histories, 17D and FNV vaccine strains are relatively dissimilar at the molecular level in the E protein by sequence analysis (Jennings et al., 1993 b) and by T1 oligonucleotide fingerprinting (Deubel et al., 1986) . However, both vaccine strains are attenuated for viscerotropic disease and have lost mosquito competence (Deubel et al., 1981; Jennings et al., 1994) . In this paper, we report the entire nucleotide sequences of the genomes of FVV and FNV viruses and speculate on the mechanisms of attenuation of YF viruses.
Methods
Cells. Monkey kidney (Vero) cells were grown at 37 °C in Eagle's minimal essential medium (EMEM; Sigma) supplemented with 10% heat-inactivated fetal calf serum (FCS; Sigma), 2 mM-L-glutamine (Sigma) and antibiotics. (Brazil, 1935;  human; stub p8, mosq pl, Vero pl) and YF69056 (Nigeria, 1948;  human; smb p3, AP61 pl; Vero pl) were also included in this study. The viruses were propagated by infection of slightly subconfluent monolayers of Vero cells at an m.o.i, of 1 p.f.u./cell. After 30 min adsorption, EMEM containing 2 % FCS and 2 mM-L-glutamine was added and cultures were incubated at 37 °C for up to 5 days.
Monkey and mouse neurovirulence studies. These were performed as described by Jennings et al. (1994) . Briefly, groups of eight or more, 3-to 4-week-old mice were inoculated with different doses of virus by the intracerebral and intranasal routes and lethality and average survival times calculated. All four FNV viruses were compared to each other in three simultaneous experiments using 17D vaccine virus as a control. For monkey neurovirulence tests, 5 × 104 p.f.u, virus was inoculated directly into the brain as recommended for the World Health Organization YF 17D vaccine monkey neurovirulence test using 17D vaccine virus as a control. Only one monkey was used for each FNV virus except FNV-NT where two monkeys were used. Viral RNA extraction. Cell debris was removed from culture media by centrifugation at 1000 g for 10 min and 1 ml of virus-containing cell culture supernatant was incubated at 37 °C for 30 min with 100 gg of proteinase K. Subsequently, 100 gl 10% SDS was added and the samples were incubated for a further 15 min at 37 °C. tRNA carrier (20 gg) was then added to the samples and mixed by vortexing. Viral RNA (vRNA) was extracted with an equal volume of phenolchloroform (1 : l) and then precipitated with 2 vols of ice-cold ethanol and 0.1 vol. 3 M-sodium acetate at 20 °C overnight. The vRNA was resuspended in TNE (50 mM-Tris, 10 mM-NaC1 and 5 mM-EDTA) and stored at -20 °C prior to use.
Cloning and sequencing. Thirty-four oligonucleotide primers were designed and synthesized based on the published 17D-204 ATCC genomic sequence (Rice et al., 1985) . Heat denatured vRNA was reverse-transcribed from the antisense primer by incubation at 55 °C for at least 1 h with RAV 2 reverse transcriptase (Amersham). Specific regions of first strand eDNA were then amplified using Taq DNA polymerase (Boehringer) and a hot start program with the appropriate sense primer. The amplification proceeded through a total of 30 cycles consisting of denaturation at 94 °C (40 s), annealing at 52 °C (1 min) and primer extension at 72 °C (10 min). The cDNAs were directly ligated into the TA cloning vector PCR II (Invitrogen) and cloned into competent E. colt INV~F' cells. Positive colonies were selected by bluewhite screening and restriction enzyme digestion.
The nucleotide sequences of the eDNA inserts were determined by the dideoxynucleotide chain termination method. Universal or specific primers were annealed to alkaline-denatured double-stranded template DNA. The clones were sequenced in both directions using the Sequenase version 2 sequencing kit (US Biochemical Corp.). The [~S]dATP-labelled reaction products were separated on 5% polyacrylamid~7 M-urea gels of 0.4 mm thickness. For each virus strain two or more clones were sequenced.
Sequence analysis. Computer analyses of nucleic acid sequence data and deduced amino acid sequences were performed using the MICROGENIE (Queen & Korn, 1984) and PCGENE (Intelligenetics) programs.
Due to the size of this project, the sequence of FVV was undertaken first and compared to the published sequence of Asibi virus (Hahn et al., 1987) . When nucleotide differences were identified they were confirmed by separate RT-PCR, cloning and sequencing. Subsequently, FNV-IP was sequenced and sequence differences from FVV were confirmed by separate RT-PCR, cloning and sequencing.
Results

Biological studies on FNV and FVV viruses
In our laboratory we have four ' isolates' of FNV, which were termed FNV-IP (Institut Pasteur, France), FNV-NT (Porton Down, UK), FNV-Yale (Yale University) and FNV-FC (Centers for Disease Control, Fort Collins, USA) after the laboratories which provided the isolates. Since the exact passage history of these FNV derivatives was unclear, we examined the mouse and monkey neurovirulence of the viruses to determine that the phenotype of the viruses was the same as described 
previously (Theiler, 1951) (Table 1) . Of the four FNV isolates, FNV-FC was the only virus which was not neurovirulent in weanling mice following intranasal inoculation (Gibson et al., 1990) and took longer to kill mice following intracerebral inoculation. FNV-NT was the only FNV virus not lethal for cynomologus monkeys. It failed to kill two monkeys after intracerebral inoculation, whereas FNV-IP and FNV-FC were lethal by this route with the average survival time of the monkey receiving FNV-FC virus longer than that receiving FNV-IP virus (9 days versus 6 days, respectively). Examination of the literature revealed that the biological properties previously reported for FNV (Theiler, 1951) most closely resemble those of FNV-IP. Therefore, we sequenced the genome of FNV-IP and compared it to that of FVV to allow the optimum comparison with biological data.
Relationship of FVV with wild-type virus Asibi
Comparison of the nucleotide and amino acid sequences of wild-type viruses FVV and Asibi (Hahn et al., 1987) 
revealed that the two viruses differed by 23 nucleotides encoding nine amino acid substitutions at positions E-227 [E (Asibi)~ G (FVV)], E-331 (K--* R), E-407 (A ---, V), NS1-228 (L --* P), NS3-25 (Y ---, S), NS3-279 (V ~ I), NS4B-145 (E --* K), NS4B-246 (K --* E) and NS5-2 (S --, R).
Compar&on of nucleotide and deduced amino sequences of FNV-IP and FVV viruses
Re-examination of the E protein gene sequence of FNV-IP virus reported by Jennings et al. (1993b) revealed that nucleotide 1223 was identical to that in FVV and did not code for an amino acid substitution at E-84 as previously reported. Consequently, this mutation has been excluded from this study.
Comparison of the nucleotide sequences of the FNV-IP virus and its parent FVV revealed that there were a total of 77 nucleotide changes, of which 35 encoded amino acid substitutions ( Table 2 ). The distribution of nucleotide changes and amino acid substitutions is summarized in Table 3 . The nucleotide changes were scattered throughout the genome, with only the 5' non- 
No.* FVV FNV-IP FNV-FC FNV-NT FNV-Yale Amino acid
* Nucleotides are numbered from the 5' terminus of the genome. :~ No amino acid difference.
coding region identical for both viruses (Table 3 ). The highest frequencies of nucleotide changes were seen in the C (1.65 %), NS2A (1.60%) and 2K (1.45%) protein genes; the E (0.81%), NS1 (0"82%) and NS4B (0"80%) protein genes and the 3' non-coding region (0"78 %) also showed a relatively high mutation rate. The 2K, NS2A and NS4B proteins have the greatest rate of amino acid substitutions (4.35 %, 1'80 % and 2.00 %, respectively). The C, M and E proteins also exhibit a relatively high rate of substitutions (1.65%, 1.33% and 1.42%, respectively).
Comparison of the nucleotide and deduced amino acid sequences of the structural protein genes of the four FNV isolates
Since the four FNV isolates had been shown to have different biological properties (Table 1) , the structural protein genes of the viruses were sequenced and compared (Table 4 ). The four FNV viruses were identical in the 5' non-coding, C, prM and M protein genes other than a single nucleotide difference at position 844 of FNV-NT which did not encode an amino acid substitution. Thus, all four FNV viruses shared amino acid substitutions, previously identified between FVV and FNV-IP, at C-80, C-90, prM-25 and M-35. Comparison of the E protein sequences revealed that only three (E-54, E-227 and E-249) of the seven amino acid substitutions from FVV to FNV-IP were common to all four FNV viruses (Table 4) . FNV-NT had six unique E protein amino acids at positions E-139, E-140, E-151, E-153, E-155 and E-288 while FNV-IP was unique at E-142 and E-407 and FNV-Yale at E-7, E-61 and E-407. 
Comparison of nucleotide and deduced amino acid sequences of FNV-IP and 17D vaccine viruses with wildtype viruses
Comparison of FNV-IP and 17D-204 virus genomes showed that there was a total of 127 nucleotide differences between them, leading to 59 amino acid differences. However, two common nucleotide changes between FVV and FNV, and Asibi and 17D-204 were identified at nucleotide positions 854 and 7171 which lead to two amino acid substitutions at positions M-35 (L-*F) and NS4B-95 (I~M). To further investigate these common nucleotide changes, vaccine viruses 17DD-Senegal, FNV-Yale, FNV-FC and FNV-NT, and wildtype viruses Tr-4205, 1337, MR896, YF69056, Dak 1279 and JSS were also sequenced around M-35 and NS4B-95. As can be seen in Table 5 , the substitutions at M-35 and NS4B-95 from wild-type virus to FNV, 17D-204 and 17DD vaccine derivatives were conserved. On the basis of the viruses examined, this indicates that these two amino acid substitutions were selected during the attenuation processes of both Asibi and FVV viruses.
Discussion
Wild-type Asibi virus was isolated from a man named Asibi in Ghana in 1927, while the FVV strain was isolated from Franqois Mayali in Senegal, also in 1927. Presumably, both viruses were part of the epidemic of YF that occurred along the West African coast in 1927/28. Our results further confirm previous reports that the two viruses are genetically closely related (Deubel et al., 1986; Jennings et al., 1993b) . The genomes of Asibi and FVV viruses differ by only 23 nucleotides leading to nine amino acid differences. It is likely that these amino acid substitutions are representative of heterogeneity or different passage histories among wild-type YF viruses. For example, Lepineic et al. (1994) reported that E-331 of FVV and Asibi viruses was lysine while we have found arginine at this position for FVV. This discrepancy may reflect different passage histories of FVV since isolation.
Comparison of the genomes of FVV and FNV-IP viruses revealed that nucleotide differences and amino acid substitutions occurred throughout the genome. However, there were no nucleotide changes in the 5' noncoding region. Since neither attenuation process (FVV to FNV and Asibi to 17D) resulted in nucleotide changes in the 5' non-coding region it would suggest that this region is not involved in attenuation of wild-type YF virus.
FVV and Asibi viruses underwent very different attenuation processes to derive attenuated variants FNV and 17D. FVV was passaged through mouse brain while Asibi virus was passaged predominately through chicken tissue. Although FNV and 17D vaccine viruses have many different biological properties, both vaccine viruses have lost the ability to cause viscerotropic disease and neither virus is mosquito competent. Also, both vaccine viruses share a common 'vaccine-specific' epitope and have lost the 'wild-type-specific' epitopes in the E protein (Gould et al., 1985 (Gould et al., , 1989 Sil et al., 1992) . It is highly likely that attenuation is multigenic, involving a combination of nucleotide/amino acid mutations, but which of the mutations found in FNV virus are responsible for attenuating FVV remains to be elucidated. However, of the individual nucleotide changes, we note that there is a double nucleotide change at 10357 and 10358, just beyond the stop codon for NS5 in the 3' non-coding region, in a region of the genome which may contribute to control of RNA replication. The amino acid substitution at NS2B-60 is in the conserved central region of NS2B that has a critical role in the function of the virus-encoded serine proteinase while the isoleucine at NS5-878 in FVV is conserved in the analogous position of all flaviviruses studied to date.
When the genomes of the attenuated FNV-IP and 17D-204 ATCC viruses were compared to their wild-type parents, two common amino acid substitutions were identified at M-35 and NS4B-95. These results were confirmed by examining other wild-type, 17D and FNV vaccine strains. Therefore, we can speculate that the two amino acid substitutions are directly, or indirectly, involved in attenuation of viscerotropic disease and/or mosquito competence of wild-type YF virus.
Little is known about the function of the M protein. Previous studies have shown that E and prM glycoproteins exist as heterodimers during transport and E. Wang and others maturation in the cytoplasm of infected ceils (Wengler & Wengler, 1989) . Recent studies have shown that flaviviruses which contain prM in virions have lost or modified E protein epitopes, as recognized by monoclonal antibodies (Guirakhoo et al., 1992; Heinz et al., 1994) . Since all wild-type YF viruses examined to date are conserved at M-35, we suggest that amino acid substitutions at M-35 can lead to conformational changes in the E protein. This may in part contribute to the loss of wild-type-specific epitopes and/or gain of vaccine-specific epitopes on the E protein of vaccine viruses. Alternatively, the substitution in the M protein may affect the maturation or assembly of vaccine viruses.
The function of NS4B is unclear, although Lin et al. (1993) have suggested that it is an integral membrane protein. The results of studies in our laboratory suggest that this protein may be important in attenuation of virulence. In addition to 17D and FNV vaccine viruses having an amino acid substitution at NS4B-95, YF vaccine revertant P-16065 (Jennings et aI., 1994) has an amino acid substitution at NS4B-76 (E. Wang and others, unpublished observations) and the attenuation of wild-type Japanese encephalitis virus strain SA14 to derive live vaccine strains SA14-2-8 and SA14-14-2 includes a common amino acid substitution at NS4B-106 (Ni et al., 1995) . Clearly, further studies on the function of this protein in virus replication are necessary to elucidate the possible role of NS4B in the attenuated phenotype.
Comparison of the E protein genes of the four FNV viruses revealed heterogeneity, which is presumably due to the different passage histories of the viruses, and probably contributes to the different biological properties of the FNV isolates (Table 1) . It was surprising to find that FNV-FC was less virulent in mice than the other FNV viruses. Comparison of the E protein of the four FNV viruses revealed no residue unique to FNV-FC virus suggesting that the molecular determinant of reduced neurovirulence/neuroinvasiveness is outside the E protein. Loss of monkey neurovirulence was a notable property of FNV-NT and it is possible that one or more of the unique amino acid substitutions in the E protein (E-139, E-140, E-151, E-153, E-155 and E-288) may contribute to this phenotype. We have previously proposed that the vaccine-specific epitope recognized by monoclonal antibodies 411 and H5 (Gould et al., 1985; Sil et al., 1992) and shared by FNV, 17D-204 and 17DD viruses includes E protein amino acids 52 to 56 since 17D-204 virus has substitutions at E-52 and E-56, 17DD virus at E-52 and FNV-IP virus at E-54 (Jennings et al., 1993b) . The observation that only E-54, E-227 and E-249 were shared by all four FNV viruses substantiates our proposal that E-52 to E-56 contribute to the E protein vaccine-specific epitope. The potential role of E-54 and E-249 in attenuation requires further studies. It is unlikely that E-227 contributes to the attenuated phenotype as FVV is unique at amino acid E-227 and all other wild-type, 17D-204 and 17DD viruses sequenced to date (Rice et al., 1985; Hahn et al., 1987; BallingerCrabtree & Miller, 1990; Dupuy et al., 1989; Post et al., 1992; Jennings e t al., 1993 a) share the glutamic acid seen in the FNV viruses.
This study has identified a number of substitutions that may contribute to the attenuated phenotype of the YF vaccine viruses. Chimeric viruses derived by infectious clone technology will now be required to identify the precise mutations involved in attenuation of virulence of wild-type YF virus.
